Last reviewed · How we verify
ILV-094
At a glance
| Generic name | ILV-094 |
|---|---|
| Also known as | placebo |
| Sponsor | Wyeth is now a wholly owned subsidiary of Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis (PHASE1)
- Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis (PHASE2)
- Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis (PHASE2)
- Study of the Safety, Tolerability, PK, and PD of ILV-094 Administered IV or SC to Healthy Subjects (PHASE1)
- Study of the Safety, Tolerability, Pharmacokinetics and Pharmcodynamics of ILV-094 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |